Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).
Ishiyama S, Yamada T, Nakamura M, Enomoto M, Sugimoto K, Yokomizo H, Kosugi C, Ohta R, Ishimaru K, Sonoda H, Ishibashi K, Kuramochi H, Yoshida Y, Ichikawa D, Hirata K, Yoshida H, Hashiguchi Y, Ishida H, Koda K, Katsumata K, Sakamoto K. Ishiyama S, et al. Among authors: ohta r. Int J Clin Oncol. 2022 Aug;27(8):1300-1308. doi: 10.1007/s10147-022-02179-9. Epub 2022 May 30. Int J Clin Oncol. 2022. PMID: 35635652 Clinical Trial.
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
Matsuoka H, Yamada T, Ohta R, Yoshida Y, Watanabe T, Takahashi M, Kosugi C, Fukazawa A, Kuramochi H, Matsuda A, Sonoda H, Yoshida H, Hasegawa S, Sakamoto K, Otsuka T, Hirata K, Koda K; TAS CC4 Study Group. Matsuoka H, et al. Among authors: ohta r. Int J Clin Oncol. 2022 Dec;27(12):1859-1866. doi: 10.1007/s10147-022-02243-4. Epub 2022 Oct 6. Int J Clin Oncol. 2022. PMID: 36201089 Clinical Trial.
480 results